MovDisordV3, PascalFrancis, Corpus, bibRecord, 002745

Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease

Identifieur interne : 002745 ( PascalFrancis/Corpus ); précédent : 002744; suivant : 002746

Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease

Auteurs : J. E. Rice ; R. Antic ; Philip D. Thompson

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0368085

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Chimiothérapie, Antiparkinsonien, Dyskinésie, Appareil respiratoire pathologie, Respiration, Traitement, Toxicité, Etude cas, Personne âgée, Mâle.

English descriptors

KwdEn :
- Antiparkinson agent, Case study, Chemotherapy, Dyskinesia, Elderly, Levodopa, Male, Parkinson disease, Respiration, Respiratory disease, Toxicity, Treatment.

Abstract

Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on 2 patients with PD in whom the introduction or augmentation of L-dopa therapy was associated with the development of irregular and rapid breathing. Analysis of breathing patterns before and after L-dopa demonstrated a striking change in respiratory rate after administration of L-dopa, with the emergence of irregular tachypnea alternating with brief periods of apnea, in a pattern consistent with a central origin. In both cases, the temporal relationship of the respiratory disturbance to the administration of L-dopa suggested a peak-dose drug effect. Previous reports of L-dopa-induced respiratory dyskinesia are reviewed, and the potential mechanisms whereby L-dopa might influence the central control of respiration to produce irregular breathing patterns are discussed.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease`
A11	`01`	`1`		`@1 RICE (J. E.)`
A11	`02`	`1`		`@1 ANTIC (R.)`
A11	`03`	`1`		`@1 THOMPSON (Philip D.)`
A14	`01`			`@1 Department of Neurology, Royal Adelaide Hospital @2 Adelaide @3 AUS @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 Thoracic Medicine Unit, Royal Adelaide Hospital @2 Adelaide @3 AUS @Z 2 aut.`
A14	`03`			`@1 University Department of Medicine, Royal Adelaide Hospital @2 Adelaide @3 AUS @Z 3 aut.`
A20				`@1 524-527`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000108224770140`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 18 ref.`
A47	`01`	`1`		`@0 02-0368085`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on 2 patients with PD in whom the introduction or augmentation of L-dopa therapy was associated with the development of irregular and rapid breathing. Analysis of breathing patterns before and after L-dopa demonstrated a striking change in respiratory rate after administration of L-dopa, with the emergence of irregular tachypnea alternating with brief periods of apnea, in a pattern consistent with a central origin. In both cases, the temporal relationship of the respiratory disturbance to the administration of L-dopa suggested a peak-dose drug effect. Previous reports of L-dopa-induced respiratory dyskinesia are reviewed, and the potential mechanisms whereby L-dopa might influence the central control of respiration to produce irregular breathing patterns are discussed.
C02	`01`	`X`		`@0 002B02U07`
C02	`02`	`X`		`@0 235`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 06`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 06`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 06`
C03	`05`	`X`	`FRE`	`@0 Dyskinésie @5 07`
C03	`05`	`X`	`ENG`	`@0 Dyskinesia @5 07`
C03	`05`	`X`	`SPA`	`@0 Disquinesia @5 07`
C03	`06`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 10`
C03	`06`	`X`	`ENG`	`@0 Respiratory disease @5 10`
C03	`06`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 10`
C03	`07`	`X`	`FRE`	`@0 Respiration @5 11`
C03	`07`	`X`	`ENG`	`@0 Respiration @5 11`
C03	`07`	`X`	`SPA`	`@0 Respiración @5 11`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`09`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`09`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`10`	`X`	`FRE`	`@0 Etude cas @5 19`
C03	`10`	`X`	`ENG`	`@0 Case study @5 19`
C03	`10`	`X`	`SPA`	`@0 Estudio caso @5 19`
C03	`11`	`X`	`FRE`	`@0 Personne âgée @5 20`
C03	`11`	`X`	`ENG`	`@0 Elderly @5 20`
C03	`11`	`X`	`SPA`	`@0 Anciano @5 20`
C03	`12`	`X`	`FRE`	`@0 Mâle @5 21`
C03	`12`	`X`	`ENG`	`@0 Male @5 21`
C03	`12`	`X`	`SPA`	`@0 Macho @5 21`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`07`	`X`	`FRE`	`@0 Mouvement involontaire @5 53`
C07	`07`	`X`	`ENG`	`@0 Involuntary movement @5 53`
C07	`07`	`X`	`SPA`	`@0 Movimiento involuntario @5 53`
C07	`08`	`X`	`FRE`	`@0 Trouble neurologique @5 54`
C07	`08`	`X`	`ENG`	`@0 Neurological disorder @5 54`
C07	`08`	`X`	`SPA`	`@0 Trastorno neurológico @5 54`
N21				`@1 203`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0368085 INIST
ET :	Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease
AU :	RICE (J. E.); ANTIC (R.); THOMPSON (Philip D.)
AF :	Department of Neurology, Royal Adelaide Hospital/Adelaide/Australie (1 aut., 3 aut.); Thoracic Medicine Unit, Royal Adelaide Hospital/Adelaide/Australie (2 aut.); University Department of Medicine, Royal Adelaide Hospital/Adelaide/Australie (3 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 3; Pp. 524-527; Bibl. 18 ref.
LA :	Anglais
EA :	Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on 2 patients with PD in whom the introduction or augmentation of L-dopa therapy was associated with the development of irregular and rapid breathing. Analysis of breathing patterns before and after L-dopa demonstrated a striking change in respiratory rate after administration of L-dopa, with the emergence of irregular tachypnea alternating with brief periods of apnea, in a pattern consistent with a central origin. In both cases, the temporal relationship of the respiratory disturbance to the administration of L-dopa suggested a peak-dose drug effect. Previous reports of L-dopa-induced respiratory dyskinesia are reviewed, and the potential mechanisms whereby L-dopa might influence the central control of respiration to produce irregular breathing patterns are discussed.
CC :	002B02U07; 235
FD :	Parkinson maladie; Lévodopa; Chimiothérapie; Antiparkinsonien; Dyskinésie; Appareil respiratoire pathologie; Respiration; Traitement; Toxicité; Etude cas; Personne âgée; Mâle
FG :	Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Mouvement involontaire; Trouble neurologique
ED :	Parkinson disease; Levodopa; Chemotherapy; Antiparkinson agent; Dyskinesia; Respiratory disease; Respiration; Treatment; Toxicity; Case study; Elderly; Male
EG :	Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Involuntary movement; Neurological disorder
SD :	Parkinson enfermedad; Levodopa; Quimioterapia; Antiparkinsoniano; Disquinesia; Aparato respiratorio patología; Respiración; Tratamiento; Toxicidad; Estudio caso; Anciano; Macho
LO :	INIST-20953.354000108224770140
ID :	02-0368085

Links to Exploration step

Pascal:02-0368085

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease</title>
<author><name sortKey="Rice, J E" sort="Rice, J E" uniqKey="Rice J" first="J. E." last="Rice">J. E. Rice</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Antic, R" sort="Antic, R" uniqKey="Antic R" first="R." last="Antic">R. Antic</name>
<affiliation><inist:fA14 i1="02"><s1>Thoracic Medicine Unit, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson, Philip D" sort="Thompson, Philip D" uniqKey="Thompson P" first="Philip D." last="Thompson">Philip D. Thompson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>University Department of Medicine, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0368085</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0368085 INIST</idno>
<idno type="RBID">Pascal:02-0368085</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002745</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease</title>
<author><name sortKey="Rice, J E" sort="Rice, J E" uniqKey="Rice J" first="J. E." last="Rice">J. E. Rice</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Antic, R" sort="Antic, R" uniqKey="Antic R" first="R." last="Antic">R. Antic</name>
<affiliation><inist:fA14 i1="02"><s1>Thoracic Medicine Unit, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson, Philip D" sort="Thompson, Philip D" uniqKey="Thompson P" first="Philip D." last="Thompson">Philip D. Thompson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>University Department of Medicine, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Elderly</term>
<term>Levodopa</term>
<term>Male</term>
<term>Parkinson disease</term>
<term>Respiration</term>
<term>Respiratory disease</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Dyskinésie</term>
<term>Appareil respiratoire pathologie</term>
<term>Respiration</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Etude cas</term>
<term>Personne âgée</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on 2 patients with PD in whom the introduction or augmentation of L-dopa therapy was associated with the development of irregular and rapid breathing. Analysis of breathing patterns before and after L-dopa demonstrated a striking change in respiratory rate after administration of L-dopa, with the emergence of irregular tachypnea alternating with brief periods of apnea, in a pattern consistent with a central origin. In both cases, the temporal relationship of the respiratory disturbance to the administration of L-dopa suggested a peak-dose drug effect. Previous reports of L-dopa-induced respiratory dyskinesia are reviewed, and the potential mechanisms whereby L-dopa might influence the central control of respiration to produce irregular breathing patterns are discussed.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RICE (J. E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ANTIC (R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>THOMPSON (Philip D.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Thoracic Medicine Unit, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University Department of Medicine, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>524-527</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000108224770140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>18 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0368085</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on 2 patients with PD in whom the introduction or augmentation of L-dopa therapy was associated with the development of irregular and rapid breathing. Analysis of breathing patterns before and after L-dopa demonstrated a striking change in respiratory rate after administration of L-dopa, with the emergence of irregular tachypnea alternating with brief periods of apnea, in a pattern consistent with a central origin. In both cases, the temporal relationship of the respiratory disturbance to the administration of L-dopa suggested a peak-dose drug effect. Previous reports of L-dopa-induced respiratory dyskinesia are reviewed, and the potential mechanisms whereby L-dopa might influence the central control of respiration to produce irregular breathing patterns are discussed.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U07</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>235</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Respiration</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Respiration</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Respiración</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Case study</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Elderly</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Anciano</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Mâle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Male</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Macho</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>53</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>54</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>54</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>54</s5>
</fC07>
<fN21><s1>203</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0368085 INIST</NO>
<ET>Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease</ET>
<AU>RICE (J. E.); ANTIC (R.); THOMPSON (Philip D.)</AU>
<AF>Department of Neurology, Royal Adelaide Hospital/Adelaide/Australie (1 aut., 3 aut.); Thoracic Medicine Unit, Royal Adelaide Hospital/Adelaide/Australie (2 aut.); University Department of Medicine, Royal Adelaide Hospital/Adelaide/Australie (3 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 3; Pp. 524-527; Bibl. 18 ref.</SO>
<LA>Anglais</LA>
<EA>Symptomatic respiratory disturbance as a consequence of levodopa (L-dopa) therapy for Parkinson's disease (PD) has been described only rarely and may be underrecognized in clinical practice. We report on 2 patients with PD in whom the introduction or augmentation of L-dopa therapy was associated with the development of irregular and rapid breathing. Analysis of breathing patterns before and after L-dopa demonstrated a striking change in respiratory rate after administration of L-dopa, with the emergence of irregular tachypnea alternating with brief periods of apnea, in a pattern consistent with a central origin. In both cases, the temporal relationship of the respiratory disturbance to the administration of L-dopa suggested a peak-dose drug effect. Previous reports of L-dopa-induced respiratory dyskinesia are reviewed, and the potential mechanisms whereby L-dopa might influence the central control of respiration to produce irregular breathing patterns are discussed.</EA>
<CC>002B02U07; 235</CC>
<FD>Parkinson maladie; Lévodopa; Chimiothérapie; Antiparkinsonien; Dyskinésie; Appareil respiratoire pathologie; Respiration; Traitement; Toxicité; Etude cas; Personne âgée; Mâle</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Mouvement involontaire; Trouble neurologique</FG>
<ED>Parkinson disease; Levodopa; Chemotherapy; Antiparkinson agent; Dyskinesia; Respiratory disease; Respiration; Treatment; Toxicity; Case study; Elderly; Male</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Involuntary movement; Neurological disorder</EG>
<SD>Parkinson enfermedad; Levodopa; Quimioterapia; Antiparkinsoniano; Disquinesia; Aparato respiratorio patología; Respiración; Tratamiento; Toxicidad; Estudio caso; Anciano; Macho</SD>
<LO>INIST-20953.354000108224770140</LO>
<ID>02-0368085</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002745 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002745 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0368085
   |texte=   Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease

Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri